{"entity":{"id":"nct03148418","kind":"trial","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","aka":[],"tldr":"A phase 3 trial of Atezolizumab and Bevacizumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) is a phase 3 interventional study registered as NCT03148418 by Hoffmann-La Roche, with 382 participants enrolled, started 2017-09-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: Atezolizumab and Bevacizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03148418","url":"https://clinicaltrials.gov/study/NCT03148418"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab","bevacizumab"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03148418","phase":"3","setting":"An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study","sponsor":"Hoffmann-La Roche","enrolled":382,"outcomes":[]},"route":"/trials/nct03148418/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}